Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated April 9, 2026, serves as a transaction notification for the month of April 2026. The document discloses a specific securities transaction involving a Person Discharging Managerial Responsibilities (PDMR) rather than providing comprehensive financial results for the period.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific insider transaction:
- Instrument: American Depositary Shares (ADS), ISIN: US37733W2044
- Transaction Price: $55.8400 per ADS
- Transaction Volume: 8.551 ADS
- Transaction Date: April 7, 2026
- Exchange: New York Stock Exchange (XNYS)
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely records an acquisition of notional ADS within the GSK Executive Supplemental Savings Plan account for Maya Martinez-Davis, President of US operations.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It includes a standard corporate description stating GSK is a global biopharma company focused on uniting science, technology, and talent to address disease.
Investor Verification Checklist
- Verify the current market price of GSK ADS against the transaction price of $55.84 reported on April 7, 2026.
- Confirm the identity and role of Maya Martinez-Davis as President, US, to assess the significance of the insider transaction.
- Note that this filing does not contain quarterly or annual financial performance data; refer to Form 20-F for comprehensive financial statements.